DYN vs EDSA

Dyne Therapeutics, Inc. vs Edesa Biotech, Inc. — Valuation Comparison 2026

DYN

Biotechnology
Dyne Therapeutics, Inc.
Quality
5.0
out of 10
Value Trap
18
SAFE
Price
$18.56
Last close
Models
10/13
Active
VS

EDSA

Biotechnology
Edesa Biotech, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$7.86
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DYN Fair ValueDYN Upside EDSA Fair ValueEDSA Upside
Bayesian DCF Intrinsic $7.68 -58.6% $2.73 -65.2%
Earnings Power Value Intrinsic $10.61 -41.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.27 -87.7% $0.65 -91.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DYN vs EDSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DYN vs EDSA — Which Stock Is More Undervalued?

DYN scores higher with a 5.0/10 quality rating vs EDSA's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dyne Therapeutics, Inc. (DYN) and Edesa Biotech, Inc. (EDSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DYN currently trades at $18.56 with a QOC of 5.0/10, while EDSA trades at $7.86 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).